Biopolymer-based biomaterial containing gold nanoparticles-bioactive glass for bone regeneration in a complicated tibial fracture in a dog: a case report
Aștilean AN., Dreancă A., Ober C., Oros NV., Peștean CP., Mârza SM.
Clinical Trial, published in Front Vet Sci (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Front Vet Sci (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41078495
- PMCID
- PMC12509738
- DOI
- 10.3389/fvets.2025.1568666
Abstract (original English)
A revision surgery for a tibial fracture in a dog, complicated by a secondary fracture site, implant migration, breakage, and bending of the initial implants, was described. After diaphyseal tibial osteotomy, the resulting gaps and bone defects were filled with the alginate-pullulan-bioactive glass-gold nanoparticles (Alg-Pll-BGAuSP) composite. The objective of applying this composite was to stimulate cell proliferation, based on its demonstrated bioactive effect, biodegradability, biocompatibility, and osteoinductive properties. The regenerative process was monitored both clinically and radiologically, with the aim of achieving an improved outcome and enhancing the welfare of the animal. At 12 weeks postoperatively, the implants were removed, and the limb resumed its original function. The application of this biomaterial enhanced the healing of a long bone defect, thereby promoting the formation of high-quality bone tissue in a relatively short time, despite the absence of anastomosis at the defect margins and the complexity of the case. Thus, the Alg-Pll-BGAuSP composite appears to be a viable treatment scaffold for further bone regeneration clinical trials. This first clinical report supports its potential as a scaffold for bone regeneration in complicated fractures.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.